OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30

Outlook Therapeutics, Inc.

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026

$0.49+0.00 (+0.98%)

Close on Oct 19, 2026

Market cap: $67.41M
P/E (TTM): –
Dividend yield: –

Outlook Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30	FY 2020 2020-09-30	FY 2019 2019-09-30	FY 2018 2018-09-30	FY 2017 2017-09-30	FY 2016 2016-09-30	FY 2015 2015-09-30
Revenue	1.41	–	–	–	–	–	8.15	3.09	3.81	2.98	5.22
Cost of Revenue	1.36	–	–	–	–	–	–	–	–	–	–
Gross Profit	0.06	–	–	–	–	–	–	–	–	–	–
Research & Development	27	42	26	42	39	26	24	19	24	33	39
Selling, General & Admin	40	30	–	–	–	–	–	–	–	–	–
General & Administrative	–	30	27	21	13	9.97	9.37	14	16	22	13
Operating Expenses	–	–	–	–	52	37	44	33	40	54	52
Operating Income	-67	-72	-53	-63	-52	-37	-36	-30	-36	-51	-47
Interest Expense	–	3.16	2.53	–	–	1.76	3.47	3.89	5.63	1.85	2.30
Interest & Investment Income	0.09	0.91	0.97	–	–	–	–	–	–	–	–
Income from Equity Investments	-0.14	-0.10	-0.01	-0.05	-0.05	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	-0.06	-0.01	–
Pretax Income	-64	-75	-59	-66	-53	-39	-38	-34	-38	-53	-49
Income Tax Expense	-1.55	0.00	0.00	0.00	0.00	-3.27	-3.41	-3.65	0.50	0.10	-0.19
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	-53	-49
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	-1.28
Net Income	-62	-75	-59	-66	-53	-35	-35	-30	-39	-53	-47
Preferred Dividends	–	–	–	–	–	–	–	–	0.02	–	–
Net Income to Common	-62	-75	-59	-66	-53	-49	-36	-48	-40	-63	-53
EPS (Basic)(per share)	-1.79	-4.06	-4.72	-6.20	-7.00	-13.40	-39.60	-194.80	-267.20	-587.20	-868.80
EPS (Diluted)(per share)	-1.79	-4.06	-4.72	-6.20	-7.00	-13.40	-39.60	-194.80	-288.00	-587.20	-868.80
Shares Outstanding (Basic, Weighted)(shares)	35	19	13	11	7.63	3.63	0.91	0.25	0.15	0.11	0.06
Shares Outstanding (Diluted, Weighted)(shares)	35	19	13	11	7.63	3.63	0.91	0.25	0.15	0.11	0.06
EBITDA	-67	-72	-53	-63	-51	-36	-33	-27	-33	-49	-45
Net Interest Income	-0.28	-3.16	-1.56	-1.49	-0.94	-1.76	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: -161.0%
Operating margin: -3935.9%
Net margin: -4324.1%
Return on equity, FY2025: 118.6%

Financial strength

Current ratio: 0.81
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 39.2%

Valuation

P/E ratio: –
Price to sales: 47.69
Price to book: –
Dividend yield: –